Glenmark Pharma Launches Generic Sunitinib Oral Capsules

Glenmark Pharmaceuticals, A Research-Led, Global Integrated Pharmaceutical Company, Launched Sutib, The Generic Version Of Sunitinib Oral Capsules To Treat Kidney Cancer In India.The Drug Is Launched At A Mrp That Is Approximately 96 Per Cent Lower Than The Mrp Compared To The Innovator Brand, Priced At Rs. 7,000 (50 Mg), Rs. 3,600 (25 Mg) And Rs. 1,840 (12.5 Mg) Per Month. Sunitinib Is Also Approved By The Us Food And Drug Administration (Fda).Kidney Cancer (Renal Cell Carcinoma) Is A Disease Of Uncontrolled Cell Growth In The Lining Of Small Tubes In The Kidney. In The Past Decade, Advances In Research And Drug Development Have Begun To Shift The Paradigm Of This Disease.Sunitinib Is An Oral Multi-Kinase Inhibitor (Mki), Works By Blocking Several Enzymes That Promote Cell Growth. It Is Useful For The Treatment Of Certain Patients With Gastrointestinal Stromal Tumors And Advanced Renal Cell Carcinoma. It Is Also Approved For Patients With Certain Type Of Pancreatic Neuroendocrine Tumours.According To A Globocan 2020 Report, There Are Close To 40,000 Patients With Renal Cancer In India. For Over A Decade, Sunitinib Has Been Well Recognized As One Of The "Gold-Standard" Of Care In Cases Of Fast-Spreading (Metastatic) Renal Cancer. Research Shows That Sunitinib Alone Has Helped Reduce The Risk Of Progression Of Renal Cancer By 58%.Commenting On The Launch, Alok Malik, Group Vice President And Business Head, India Formulations, Said, "Oncology Is An Important Focus Area For Glenmark. We Recognize That Advanced Kidney Cancer Is A Complex Disease And Patients In India Are Faced With Limited Treatment Options. Glenmark Is Committed To Bringing Targeted And Effective Medicines At An Affordable Cost To Physicians And Their Patients."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!